Objective:To investigate application evaluation of acceptance and commitment therapy among patients undergoing early stage of peritoneal dialysis.Methods:A total of 100 patients who undergoing early stage of peritoneal dialysis from March 2018 to January 2020 in Nephrology of Shanghai Tongji Hospital were assigned to the experimental groupand control group according to the random number table method with 50 cases in each group. The control group received routine nursing care, while the experimental group implemented 6-week acceptance and commitment therapy. The effect was assessed by Self-report Psychosocial Adjustment to Illness Scale (PAIS-SR) and Self-perceived Burden Scale (SPBS).Results:After intervention, the scores of health care, working ability, family relationship, communication, entertainment and psychological status dimensionand total PAIS-SR were (7.93 ± 1.50), (9.11 ± 1.38), (6.61 ± 1.73), (6.82 ± 1.42), (6.82 ± 1.66), (8.18 ± 1.79), (50.91 ± 4.24) points in the experimental group, which were lower than those in the control group (9.63 ± 1.22), (10.78 ± 1.64), (7.50 ± 2.07), (7.57 ± 2.05), (7.50 ± 1.07), (9.43 ± 1.92), (58.02 ± 4.13) points, the differences were statistically significant between the two groups( t values were 2.02-8.07, all P<0.05). After intervention, the scores of physical burden, emotional burden dimension and total SPBS were (9.68 ± 1.75), (14.54 ± 1.76), (30.89 ± 2.99) points in the experimental group, which were lower than those in the control group (10.80 ± 1.82), (16.11 ± 2.04), (33.65 ± 3.19) points, the differences were statistically significant ( t=2.98, 3.89, 4.24, all P<0.05). Conclusions:Acceptance and commitment therapy can improve the ability of disease adaptability and decrease self-perceived burden in patients undergoing early stage of peritoneal dialysis.

Non-alcoholic fatty liver disease has now become a common hepatic metabolic disease, but there is no universally approved therapeutic drug on the market, so there is an urgent need to explore relevant therapeutic drugs. Several studies have shown that the thyroid hormone receptor β, which is specifically expressed in the liver, plays an important role in lipid metabolism. T3 analogs and thyroid hormone receptor β-specific agonists have been developed for thyroid hormone receptor β. Many studies have shown that it can inhibit hepatic triglyceride synthesis, increase hepatic cholesterol clearance, reduce lipid deposition, and at the same time partly increase insulin sensitivity, promote glucose metabolism, and improve inflammation. Therefore, it has become a therapeutic drug with great potential for the treatment of non-alcoholic fatty liver disease. Herein, the mechanism, clinical research and drug development status are reviewed in order to provide new ideas for targeted therapy of non-alcoholic fatty liver disease with thyroid hormone receptor β.